
Oric Pharmaceuticals, Inc. — Investor Relations & Filings
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer. The company's platform addresses the primary mechanisms of therapeutic resistance—innate, acquired, and bypass—with the goal of making existing treatments more effective and durable. Its pipeline includes several targeted therapeutics in clinical development. Key programs include enozertinib (ORIC-114), an inhibitor being studied in non-small cell lung cancer (NSCLC) with specific EGFR/HER2 mutations, and ORIC-944, which is in trials for prostate cancer. Oric employs a precision oncology approach, using biomarkers to identify patient populations most likely to respond to its treatments.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEF 14A - Oric Pharmaceuticals, Inc. (0001796280) (Filer) | 2026-04-28 | English | |
| 4 - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-26 | English | |
| 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | |
| 10-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | |
| 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 38155746 | DEF 14A - Oric Pharmaceuticals, Inc. (0001796280) (Filer) | 2026-04-28 | English | ||
| 32898467 | 4 - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-26 | English | ||
| 32898472 | 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | ||
| 32898475 | 10-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | ||
| 32898468 | 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | ||
| 31755143 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 13223467 | Major Shareholding Notification 2026 | 2026-01-21 | English | ||
| 13223468 | Director's Dealing 2026 | 2026-01-21 | English | ||
| 13223469 | Regulatory Filings 2026 | 2026-01-16 | English | ||
| 13223470 | Regulatory Filings 2026 | 2026-01-16 | English | ||
| 13223471 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223472 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223473 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223474 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223475 | Director's Dealing 2026 | 2026-01-06 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Alligator Bioscience
Clinical-stage biotech developing tumor-directed immuno-onc…
|
ATORX | SE | Manufacturing |
|
Allmed Medical Products Co., Ltd
Manufacturer of medical dressings, surgical kits, and dispo…
|
002950 | CN | Manufacturing |
|
Allogene Therapeutics, Inc.
Develops off-the-shelf allogeneic CAR T therapies for cance…
|
ALLO | US | Manufacturing |
|
Almirall S.A.
Global biopharmaceutical company specializing in medical de…
|
ALM | ES | Manufacturing |
|
ALNYLAM PHARMACEUTICALS, INC.
A biopharmaceutical company developing RNA interference (RN…
|
ALNY | US | Manufacturing |
|
Alpa Laboratories Limited
WHO-GMP certified manufacturer of human and veterinary phar…
|
ALPA | IN | Manufacturing |
|
Alpha Cognition Inc.
A biopharmaceutical company developing treatments for neuro…
|
ACOG | CA | Manufacturing |
|
Alphamab Oncology
Innovative biopharma specializing in differentiated anti-tu…
|
9966 | KY | Manufacturing |
|
Alpha Teknova, Inc.
Manufacturer of critical reagents for the life sciences ind…
|
TKNO | US | Manufacturing |
|
ALTERITY THERAPEUTICS LTD
A clinical-stage biotech developing novel treatments for ne…
|
ATHE | US | Manufacturing |
Oric Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32131/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32131 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32131 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32131 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32131}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Oric Pharmaceuticals, Inc. (id: 32131)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.